시장보고서
상품코드
1164939

세포치료 제조 시장 : 제조되는 세포 유형별, 세포 유래별, 사업 규모별, 제조 목적별, 주요 지역별 : 업계 동향과 세계 예측(2022-2035년)

Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

발행일: | 리서치사: Roots Analysis | 페이지 정보: 영문 553 Pages | 배송안내 : 1-2일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 세포치료 제조(Cell Therapy Manufacturing) 시장에 대해 조사했으며, 시장 개요, 제조되는 세포 유형별/세포 유래별/사업 규모별/제조 목적별/주요 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 요약

제3장 서론

제4장 시장 개요

제5장 규제 상황

  • 본 장의 개요
  • 현재의 시나리오
  • 세포치료 제조 규제 인정
  • 세포치료 임상 단계 제조에 관한 가이드라인 개요
  • 세포치료 임상 단계 제조에 대한 기존 과제

제6장 과제를 극복하기 위한 로드맵

제7장 세포치료 제조 자동화 기술

제8장 개요 : 업계 관계자

  • 본 장의 개요
  • 북미의 서비스 제공업체
  • 유럽의 서비스 제공업체
  • 아시아태평양의 서비스 제공업체

제9장 개요 : 산업계 이외 참여 기관

제10장 비영리 단체의 역할

제11장 임상시험 분석

  • 본 장의 개요
  • 범위와 조사 방법
  • 세포치료 : 임상시험 분석

제12장 파트너십과 협업

제13장 최근 확장

  • 본 장의 개요
  • 세포치료 제조 : 확대 리스트

제14장 대형 제약회사의 이니셔티브

제15장 캐퍼시티 분석

제16장 수요 분석

  • 본 장의 개요
  • 범위와 조사 방법
  • 세포치료 제조에 대한 세계 수요
  • 세포치료 제조에 대한 세계 임상 수요
  • 세포치료 제조의 세계 상업적 수요

제17장 원가 분석

제18장 자체 제작 및 구입 선택 의사결정 프레임워크

제19장 세포치료 제조 조직의 총소유비용

제20장 시장 규모와 기회 분석

제21장 중요 인사이트

제22장 SWOT 분석

제23장 결론

제24장 조사 분석

제25장 인터뷰 기록

제26장 부록 1 : 표 형식 데이터

제27장 부록 2 : 기업 및 조직 리스트

LSH 22.12.09

INTRODUCTION

Driven by numerous developmental breakthroughs and results of studies demonstrating the vast potential of cellular therapies in the treatment of rare disorders, this therapeutic modality has garnered considerable attention of players engaged in the healthcare industry, in the past few years. In this context, it is worth noting that, since 2019, over 1,035 clinical studies focused on such cell therapy candidates have been initiated. Moreover, several commercialized cell therapies have emerged as top selling drugs in the healthcare industry. For instance, Kymriah® has registered sales worth over USD 1.5 billion since its launch in 2018. Considering the sufficient body of evidence validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders has now shifted to optimizing the cell therapy manufacturing process. Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products, thereby, making such products more affordable. One such emerging concept, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. However, the delicate nature of steps involved in the cell therapy production process is known to hinder the overall automation process. Further, the lack of specialized infrastructure and limited expertise available in this domain are some of the known challenges impacting the growth of this segment.

At present, the market landscape for cell therapy manufacturing is fragmented, featuring a mix of in-house manufacturers and contract service providers. Further, in order to ensure the optimum use of their resources and enable additional revenue generation opportunities, a number of innovator companies engaged in this market also offer contract services, in addition to their in-house manufacturing capabilities. Considering the growing demand for cell therapies, players engaged in this industry are undertaking several initiatives to ensure that they are able to cater to the requirements of their clients. Since 2020, a considerable increase in both partnership and expansion activity has been observed within the overall cell therapy domain. It is also worth highlighting that the increasing interest and involvement of big pharma players in this market has been instrumental in escalation of the adoption of such therapies. In recent years, several big pharma players have undertaken initiatives, including establishing strategic partnerships with other industry players and carrying out expansion projects, in order to enhance their cell therapy manufacturing capabilities. Considering the ongoing efforts of stakeholders to mitigate the manufacturing associated complications and an enhanced emphasis on the advancement of such therapies, the cell therapy manufacturing market is anticipated to witness significant growth in the foreseen future.

SCOPE OF THE REPORT

The "Cell Therapy Manufacturing Market (5th Edition) by Type of Cell Manufactured (Immune Cells, Stem Cells and Others ), Source of Cell (Autologous and Allogeneic), Scale of Operation (Preclinical, Clinical and Commercial), Purpose of Manufacturing (In-house and Contract) and Key Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) - Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and future opportunities associated with the cell therapy manufacturing market, along with information on both contract manufacturers, as well as developers having in-house manufacturing capabilities, offering an in-depth analyses of the various business entities engaged in this domain, across key geographic locations. Amongst other elements, the report includes:

  • A general overview of cell therapies, along with information on the key challenges and factors influencing the cell therapy manufacturing market. It provides details on the automation tools and technologies being utilized for improving manufacturing processes and the future prospects in this domain.
  • A detailed review of the overall market landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cells manufactured (including immune cells (T cells, dendritic cells, NK cells), stem cells (adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), location of headquarters and their respective manufacturing facilities.
  • A discussion on cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
  • An overview of the various roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing processes.
  • An elaborate discussion on the role of technology automation in order to improve the current manufacturing methods, along with a comparative (qualitive) analysis of the cost differences between manual and automated processes.
  • Elaborate profiles of key industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales of operation. Each profile features a brief overview of the company, along with details related to its cell therapy manufacturing service portfolio, its manufacturing capabilities and facilities, recent partnerships and an informed future outlook.
  • Elaborate profiles of non-industry players that offer contract manufacturing services for cell therapies, featuring an overview of the organization, along with details related to its cell therapy manufacturing service portfolio and manufacturing facilities.
  • A discussion on the role of non-profit organizations, featuring a list of organizations that are actively involved in the development and production of cell-based therapies, across different geographical locations, along with information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.
  • An analysis of completed, ongoing and planned clinical trials, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active industry and non-industry players (in terms of number of clinical trials conducted) and regional distribution of trials.
  • A detailed analysis of the recent partnerships and collaborations inked by players focused on the manufacturing of cell-based therapies, during the period 2016-2022, based on several relevant parameters, such as the year of agreement, type of partnership model adopted, type of cells manufactured and scale of operation.
  • An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2016-2022, based on several relevant parameters, such as year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
  • An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
  • An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
  • Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions.
  • A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • An in-depth analysis of cell therapy manufacturers using three versatile representations, namely, a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cell manufactured, scale of operation and purpose of production, a logo landscape, based on the type of cell manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific), and type and size of organization (non-industry players, and small, mid-sized and large companies), and a schematic world map representation, highlighting the geographical location of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
  • A collection of key insights derived from the study, including a grid analysis, two logo landscapes and two schematic world map representations highlighting various offerings and details of the cell therapy manufacturing service providers across different continents.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
  • Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on relevant parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such therapies, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long-term, for the period 2022-2035. The report also features the likely distribution of the current and forecasted opportunity across important parameters, such as [A] type of cell therapy (T cell therapies, dendritic cell therapies, NK cell therapies, stem cell therapies and others), [B] source of cell (autologous and allogeneic), [C] scale of operation (clinical and commercial), [D] purpose of manufacturing (in-house and contract), and [E] key geographical regions (North America, Europe, Asia Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals:

  • Peter Coleman (Chief Executive Officer, RoslinCT)
  • Dominic Clarke (Chief Technical Officer, Cell and Gene Therapy, Discovery Life Sciences)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Gilles Devillers (General Manager, Bio Elpida)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Arik Hasson (Executive VP Research and Development, Kadimastem)
  • Fiona Bellot (Ex-Business Development Manager, Roslin CT)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
  • Victor Lietao Li (Ex- Co-Founder and Chief Executive Officer, Lion TCR)
  • Arnaud Deladeriere (Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Mathilde Girard (Ex-Department Leader, Cell Therapy Innovation and Development, Yposkesi)
  • Tim Oldham (Ex-Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various emerging trends in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market, gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

  • What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
  • What is the current, installed contract manufacturing capacity for cell therapies?
  • What are the key parameters governing the price of cell therapies?
  • What are the key recent developments (such as partnerships and expansions) that have been undertaken in the field of cell therapies?
  • What kind of partnership models are commonly adopted by stakeholders engaged in the cell therapy manufacturing domain?
  • What are the different types of initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
  • What are the different types of automated technology platforms that are available to be adopted for the development and manufacturing of cell therapies?
  • Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
  • What is the estimated total capital expenditure required to set up a cell therapy manufacturing facility?
  • What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies?
  • How is the current and future market opportunity likely to be distributed across various key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to cell-based therapies and ATMPs. It further features a detailed discussion on the manufacturing process of cell-based therapies, and associated challenges, along with information on the applications of currently approved products. Additionally, it highlights information on the different manufacturing models (centralized and decentralized) that are being used for manufacturing of cell-based therapies, as well as their associated advantages and disadvantages. Furthermore, it features details related to the scalability of cell-based therapies. The chapter also includes a brief overview of the role of automation and the need for effective supply chain management for cell-based therapies.

Chapter 4 features a detailed list of all the industry, as well as non-industry players that are actively involved in the manufacturing of cell-based therapies. It provides information on the type of cell manufactured (including immune cells (T cells, dendritic cells, NK cells), stem cells (adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cell (autologous and allogeneic), scale of operation (preclinical, clinical and commercial), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (R&D, cell culture development, quality testing, packaging, cell banking, supply chain management services, and regulatory services), location of headquarters and their respective manufacturing facilities.

Chapter 5 features a detailed discussion on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe, Japan and China. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations located across various geographies, specifically in the US.

Chapter 7 discusses the role of technology automation in order to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.

Chapter 8 features elaborate profiles of key industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales of operation. Each profile features a brief overview of the company, along with details related to its cell therapy manufacturing capabilities and facilities, recent partnerships and an informed future outlook.

Chapter 9 features elaborate profiles of non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, along with details related to its cell therapy manufacturing service portfolio and manufacturing facilities.

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different geographical locations. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.

Chapter 11 presents a detailed analysis of completed, ongoing and planned clinical trials, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, target therapeutic area, study design, most active industry and non-industry players (in terms of number of clinical trials conducted) and regional distribution of trials.

Chapter 12 features an analysis of the various partnerships and collaborations inked amongst players engaged in this domain, between 2016-2022 (till July). It includes a brief description on the various types of partnership models that are employed by stakeholders in this market, and an analysis on the trend of partnerships. It also includes analyses based on year of agreement, type of partnership, scale of operation, type of cells manufactured and most active players. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals. Further, the chapter features an analysis of the various acquisitions that have taken place in this domain, highlighting geographical activity. The analysis also features an ownership change matrix, providing insights on the involvement of private and public sector entities in this domain.

Chapter 13 presents detailed analysis on the expansions that have taken place in the cell therapy manufacturing industry, since 2016. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances were analyzed based on various parameters, including year of expansion, type of cell manufactured, scale of operation, purpose of expansion (facility expansion and new facility), location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).

Chapter 14 provides an in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.

Chapter 15 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small, mid-sized and large companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, Europe and Asia Pacific) and company size (small, mid-sized and large organizations).

Chapter 16 features a detailed analysis of the annual demand for cell therapies (in terms of number of patients), considering various relevant parameters, such as target patient population, dosing frequency and dose strength of the approved cell therapies, as well as those therapies that are currently being evaluated in clinical trials. The demand analysis has been segmented across different types of cell therapies (including CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells and stem cells), scale of operation (clinical and commercial) and regions (North America, Europe and Asia Pacific).

Chapter 17 highlights our views on various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches adopted by manufacturers in order to determine the price of its proprietary products.

Chapter 18 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 19 presents a company size-wise, detailed analysis of the total cost of ownership for cell therapy manufacturing organizations, during the period 2022-2042.

Chapter 20 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2035. The chapter presents a detailed market segmentation on the basis of type of cell therapy (T cell therapies, dendritic cell therapies, NK cell therapies, stem cell therapies and others), source of cell (autologous and allogeneic), scale of operation (clinical and commercial), purpose of manufacturing (in-house and contract), and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).

Chapter 21 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cell manufactured, scale of operation and purpose of production (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cell manufactured (immune cells and stem cells), geographical regions (North America, Europe and Asia Pacific) and the type / size of organization (non-industry, small, mid-sized and large companies). The chapter also comprises of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 22 provides a discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall cell therapy manufacturing industry.

Chapter 23 is a summary the overall report. The chapter provides the key takeaways from the report, and presents facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the cell therapy manufacturing market.

Chapter 24 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 25 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Peter Coleman (Chief Executive Officer, RoslinCT), Dominic Clarke (Chief Technical Officer, Cell and Gene Therapy, Discovery Life Sciences), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Gilles Devillers (General Manager, Bio Elpida), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Arik Hasson (Executive VP Research and Development, Kadimastem), Fiona Bellot (Business Development Manager, Roslin CT), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi), Tim Oldham (Chief Executive Officer, Cell Therapies) and Gerard MJ Bos (Chief Executive Officer, CiMaas).

Chapter 26 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 27 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentations
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Cell-based Therapies
    • 3.2.1. Comparison of Cell-based Therapies and Other Biotechnological Products
    • 3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
    • 3.2.3. Current Market Landscape of ATMPs
  • 3.3. Overview of Cell Therapy Manufacturing
  • 3.4. Cell Therapy Manufacturing Models
    • 3.4.1. Centralized Manufacturing
    • 3.4.2. Decentralized Manufacturing
  • 3.5. Scalability of Cell Therapy Manufacturing Processes
    • 3.5.1. Scale-up
    • 3.5.2. Scale-out
  • 3.6. Types of Cell Therapy Manufacturers
  • 3.7. Key Challenges for Manufacturing Cell Therapies
  • 3.8. Key Factors Influencing Cell Therapy Manufacturing
    • 3.8.1. Characterization
    • 3.8.2. Cost of Goods
  • 3.9. Automation of Cell Therapy Manufacturing Processes
  • 3.10. Cell Therapy Manufacturing Supply Chain
  • 3.11. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Cell Therapy Manufacturing (Industry Players): Overall Market Landscape
    • 4.2.1. Analysis by Company Size
    • 4.2.2. Analysis by Year of Establishment
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Company Size and Location of Headquarters
    • 4.2.5. Analysis by Year of Establishment and Location of Headquarters
    • 4.2.6. Analysis by Location of Manufacturing Facility
    • 4.2.7. Analysis by Type of Manufacturer
    • 4.2.8. Analysis by Location of Headquarters and Type of Manufacturer
    • 4.2.9. Analysis by Type of Cell Manufactured
    • 4.2.10. Analysis by Company Size and Type of Cell Manufactured
    • 4.2.11. Analysis by Location of Headquarters and Type of Cell Manufactured
    • 4.2.12. Analysis by Source of Cells
    • 4.2.13. Analysis by Type of Cell Manufactured and Source of Cells
    • 4.2.14. Analysis by Scale of Operation
    • 4.2.15. Analysis by Manufacturing Capabilities / Services Offered
    • 4.2.16. Analysis by Company Size and Services Offered
    • 4.2.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered
  • 4.3. Cell Therapy Manufacturing (Non-Industry Players): Overall Market Landscape
    • 4.3.1. Analysis by Organization Size
    • 4.3.2. Analysis by Year of Establishment
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Organization Size and Location of Headquarters
    • 4.3.5. Analysis by Year of Establishment and Location of Headquarters
    • 4.3.6. Analysis by Location of Manufacturing Facility
    • 4.3.7. Analysis by Type of Manufacturer
    • 4.3.8. Analysis by Location of Headquarters and Type of Manufacturer
    • 4.3.9. Analysis by Type of Cell Manufactured
    • 4.3.10. Analysis by Organization Size and Type of Cell Manufactured
    • 4.3.11. Analysis by Location of Headquarters and Type of Cell Manufactured
    • 4.3.12. Analysis by Source of Cells
    • 4.3.13. Analysis by Type of Cell Manufactured and Source of Cells
    • 4.3.14. Analysis by Scale of Operation
    • 4.3.15. Analysis by Manufacturing Capabilities / Services Offered
    • 4.3.16. Analysis by Organization Size and Services Offered
    • 4.3.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered

5. REGULATORY LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Current Scenario
    • 5.2.1. Regulatory Guidelines in North America
    • 5.2.2. Regulatory Guidelines in Europe
    • 5.2.3. Regulatory Guidelines in Japan
    • 5.2.4. Regulatory Guidelines in China
    • 5.2.5. Conditional Approvals
  • 5.3. Regulatory Accreditations for Cell Therapy Manufacturing
    • 5.3.1. Facilities Approved by Regulators to Manufacture Cell Therapies
  • 5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies
  • 5.5. Existing Challenges to Clinical-Stage Manufacturing of Cell Therapies
    • 5.5.1. Variability in Regulatory Guidelines across Different Geographies

6. ROADMAPS FOR OVERCOMING CHALLENGES

  • 6.1. Chapter Overview
  • 6.2. Roadmap for the US
    • 6.2.1. Cell Processing
    • 6.2.2. Cell Preservation, Distribution and Handling
    • 6.2.3. Process Automation and Data Analytics
    • 6.2.4. Process Monitoring and Quality Control
    • 6.2.5. Standardization and Regulatory Support
    • 6.2.6. Workforce Development
    • 6.2.7. Supply Chain and Logistics
  • 6.3. Roadmaps for Other Geographies
    • 6.3.1. Europe
    • 6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

  • 7.1. Chapter Overview
  • 7.2. Automation of Cell Therapy Manufacturing Processes
    • 7.2.1. Closed Systems
    • 7.2.2. Single-use Systems
    • 7.2.3. Modular Systems
  • 7.3. Growth Drivers and Roadblocks
  • 7.4. Case Studies
    • 7.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
    • 7.4.2. Automating the Cell Therapy Manufacturing Process
  • 7.5. GMP-in-a-Box
  • 7.6. List of Automated and Closed Cell Therapy Processing Systems
  • 7.7. Comparative Analysis of Manual and Automated Processes

8. PROFILES: INDUSTRY PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Service Providers in North America
    • 8.2.1 AGC Biologics
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Service Portfolio
      • 8.2.1.3. Manufacturing Facilities and Capabilities
      • 8.2.1.4. Recent Developments and Future Outlook
    • 8.2.2. Charles River Laboratories
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Service Portfolio
      • 8.2.2.3. Manufacturing Facilities and Capabilities
      • 8.2.2.4. Recent Developments and Future Outlook
    • 8.2.3. KBI Biopharma
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Service Portfolio
      • 8.2.3.3. Manufacturing Facilities and Capabilities
      • 8.2.3.4. Recent Developments and Future Outlook
    • 8.2.4. Thermo Fisher Scientific
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Service Portfolio
      • 8.2.4.3. Manufacturing Facilities and Capabilities
      • 8.2.4.4. Recent Developments and Future Outlook
  • 8.3. Service Providers in Europe
    • 8.3.1. BioNTech Innovative Manufacturing Services
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
      • 8.3.1.3. Manufacturing Facilities and Capabilities
      • 8.3.1.4. Recent Developments and Future Outlook
    • 8.3.2. Cell and Gene Therapy Catapult
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Service Portfolio
      • 8.3.2.3. Manufacturing Facilities and Capabilities
      • 8.3.2.4. Recent Developments and Future Outlook
    • 8.3.3. Lonza
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Service Portfolio
      • 8.3.3.3. Manufacturing Facilities and Capabilities
      • 8.3.3.4. Recent Developments and Future Outlook
    • 8.3.4. RoslinCT
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Service Portfolio
      • 8.3.4.3. Manufacturing Facilities and Capabilities
      • 8.3.4.4. Recent Developments and Future Outlook
  • 8.4. Service Providers in Asia Pacific
    • 8.4.1. Cell Therapies
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Service Portfolio
      • 8.4.1.3. Manufacturing Facilities and Capabilities
      • 8.4.1.4. Recent Developments and Future Outlook
    • 8.4.2. FUJIFILM Cellular Dynamics
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Service Portfolio
      • 8.4.2.3. Manufacturing Facilities and Capabilities
      • 8.4.2.4. Recent Developments and Future Outlook
    • 8.4.3. Minaris Regenerative Medicine
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Service Portfolio
      • 8.4.3.3. Manufacturing Facilities and Capabilities
      • 8.4.3.4. Recent Developments and Future Outlook
    • 8.4.4. MEDINET
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Service Portfolio
      • 8.4.4.3. Manufacturing Facilities and Capabilities
      • 8.4.4.4. Recent Developments and Future Outlook
    • 8.4.5. Nikon CeLL Innovation
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Service Portfolio
      • 8.4.5.3. Manufacturing Facilities and Capabilities
      • 8.4.5.4. Recent Developments and Future Outlook
    • 8.4.6. WuXi AppTec
      • 8.4.6.1. Company Overview
      • 8.4.6.2. Service Portfolio
      • 8.4.6.3. Manufacturing Facilities and Capabilities
      • 8.4.6.4. Recent Developments and Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
    • 9.2.1. Overview
    • 9.2.2. Operating Segments
    • 9.2.3. Service Portfolio
    • 9.2.4. Manufacturing Facilities and Capabilities
  • 9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
    • 9.3.1. Overview
    • 9.3.2. Service Portfolio
    • 9.3.3. Manufacturing Facilities and Capabilities
  • 9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
    • 9.4.1. Overview
    • 9.4.2. Service Portfolio
    • 9.4.3. Manufacturing Facilities and Capabilities
  • 9.5. Guy's and St. Thomas' GMP Facility, Guy's Hospital
    • 9.5.1. Overview
    • 9.5.2. Service Portfolio
    • 9.5.3. Manufacturing Facilities and Capabilities
  • 9.6. Laboratory for Cell and Gene Medicine, Stanford University
    • 9.6.1. Overview
    • 9.6.2. Service Portfolio
    • 9.6.3. Manufacturing Facilities and Capabilities
  • 9.7. Molecular and Cellular Therapeutics, University of Minnesota
    • 9.7.1. Overview
    • 9.7.2. Service Portfolio
    • 9.7.3. Manufacturing Facilities and Capabilities
  • 9.8. Newcastle Cellular Therapies Facility, Newcastle University
    • 9.8.1. Overview
    • 9.8.2. Service Portfolio
    • 9.8.3. Manufacturing Facilities and Capabilities
  • 9.9. Rayne Cell Therapy Suite, King's College London
    • 9.9.1. Overview
    • 9.9.2. Manufacturing Facilities and Capabilities
  • 9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
    • 9.10.1. Overview
    • 9.10.2. Manufacturing Facilities and Capabilities
  • 9.11. Sydney Cell and Gene Therapy
    • 9.11.1. Overview
    • 9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS

  • 10.1. Chapter Overview
  • 10.2. Cell Therapy Manufacturing: Non-Profit Organizations
    • 10.2.1. CellCAN
    • 10.2.2. Cell Therapy Manufacturing Cooperative Research Center
    • 10.2.3. National Cell Manufacturing Consortium (NCMC)
    • 10.2.4. California Institute of Regenerative Medicine (CIRM)
  • 10.3. Cell Therapy Manufacturing: International Societies

11. CLINICAL TRIAL ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Cell Therapies: Clinical Trial Analysis
    • 11.3.1. Analysis by Trial Registration Year
    • 11.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
    • 11.3.3. Analysis by Trial Status
    • 11.3.4. Analysis by Trial Registration Year and Trial Status
    • 11.4.5. Analysis by Trial Phase
    • 11.4.6. Analysis of Enrolled Patient Population Trial Phase
    • 11.4.7. Analysis by Type of Sponsor / Collaborator
    • 11.4.8. Analysis by Patient Segment
    • 11.4.9. Analysis by Study Design
    • 11.4.10. Most Active Players: Analysis by Number of Registered Trials
    • 11.4.11. Analysis by Number of Trials and Geography
    • 11.4.12. Analysis by Number of Trials, Trial Status and Geography
    • 11.4.13. Analysis by Enrolled Patient Population, Trial Status and Geography

12. PARTNERSHIPS AND COLLABORATIONS

  • 12.1. Chapter Overview
  • 12.2. Partnership Models
  • 12.3. Cell Therapy Manufacturing: List of Partnerships
    • 12.3.1. Analysis by Year of Partnership
    • 12.3.2. Analysis by Type of Partnership
    • 12.3.3. Analysis by Year and Type of Partnership
  • 12.4. Analysis by Type of Cell Manufactured
  • 12.5. Analysis by Scale of Operation
  • 12.6. Analysis by Region
    • 12.6.1. Continent-wise Distribution
    • 12.6.2. Country-wise Distribution
  • 12.7. Most Active Players: Analysis by Number of Partnerships
  • 12.8. Cell Therapy Manufacturing: List of Mergers and Acquisitions
    • 12.8.1. Analysis by Year of Agreement
    • 12.8.2. Analysis by Type of Agreement
    • 12.8.3. Analysis by Year of Acquisition and Type of Cell Manufactured
    • 12.8.4. Analysis by Region
      • 12.8.4.1. Continent-wise Distribution
      • 12.8.4.2. Country-wise Distribution
      • 12.8.4.3. Intercontinental and Intracontinental Deals
    • 12.8.5. Ownership Change Matrix

13. RECENT EXPANSIONS

  • 13.1. Chapter Overview
  • 13.2. Cell Therapy Manufacturing: List of Expansions
    • 13.2.1. Cumulative Year-wise Distribution
    • 13.2.2. Analysis by Type of Expansion
    • 13.2.3. Analysis by Types of Cells Manufactured
    • 13.2.4. Analysis by Scale of Operation
    • 13.2.5. Analysis by Location of Manufacturing Facility
    • 13.2.6. Analysis by Type of Expansion and Location of Manufacturing Facility
    • 13.2.7. Most Active Players: Analysis by Number of Expansions
    • 13.2.8. Most Active Players: Analysis by Area of Expansion
    • 13.2.9. Analysis by Year and Location of Manufacturing Facility

14. BIG PHARMA INITIATIVES

  • 14.1. Chapter Overview
  • 14.2. Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
    • 14.2.1. Analysis by Number of Initiatives
    • 14.2.2. Analysis by Year of Initiative
    • 14.2.3. Analysis by Type of Initiative
      • 14.2.3.1. Analysis by Type of Partnership
      • 14.2.3.2. Analysis by Type of Expansion
    • 14.2.4. Analysis by Types of Cells Manufactured
    • 14.2.5. Analysis by Scale of Operation
    • 14.2.6. Analysis of Big Pharma Players by Year of Initiative
    • 14.2.7. Analysis by Year and Type of Initiative
    • 14.2.8. Analysis of Big Pharma Players by Types of Cells Manufactured
    • 14.2.9. Analysis of Big Pharma Players by Scale of Operation
  • 14.3. Competitive Benchmarking of Big Pharmaceutical Players
    • 14.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
    • 14.3.2. Spider Web Analysis: Big Pharmaceutical Players

15. CAPACITY ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology (Industry Players)
    • 15.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 15.2.1.1. Analysis by Company Size
      • 15.2.1.2. Analysis by Scale of Operation
      • 15.2.1.3. Analysis by Location of Manufacturing Facility
      • 15.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
      • 15.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
    • 15.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 15.2.2.1. Analysis by Company Size
      • 15.2.2.2. Analysis by Scale of Operation
      • 15.2.2.3. Analysis by Location of Manufacturing Facility
      • 15.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
      • 15.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility
  • 15.3. Key Assumptions and Methodology (Non-Industry Players)
    • 15.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 15.3.1.1. Analysis by Scale of Operation
      • 15.3.1.2. Analysis by Location of Manufacturing Facility
    • 15.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 15.3.2.1. Analysis by Scale of Operation
      • 15.3.2.2. Analysis by Location of Manufacturing Facility
  • 15.4 Concluding Remarks

16. DEMAND ANALYSIS

  • 16.1 Chapter Overview
  • 16.2 Scope and Methodology
  • 16.3 Global Demand for Cell Therapy Manufacturing
  • 16.4 Global Clinical Demand for Cell Therapy Manufacturing
    • 16.4.1. Analysis by Type of Cell Therapy
    • 16.4.2. Analysis by Geography
  • 16.5. Global Commercial Demand for Cell Therapy Manufacturing
    • 16.5.1. Analysis by Type of Cell Therapy
    • 16.5.2. Analysis by Geography

17. COST PRICE ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Factors Contributing to the High Price of Cell Therapies
  • 17.3. Pricing Models for Cell Therapies
    • 17.3.1. Based on Associated Costs for T-Cell Therapies
    • 17.3.2. Based on Associated Costs for Stem Cell Therapies
    • 17.3.3. Based on Availability of Competing Products
    • 17.3.4. Based on Target Patient Segment
    • 17.3.5. Based on the Opinions of Industry Experts
  • 17.4. Cell Therapy Cost Optimization
    • 17.4.1. Role of Cost of Goods Sold
    • 17.4.2. Role of Automation
  • 17.5. Role of Cell Therapy Contract Manufacturing Organizations
  • 17.6. Reimbursement-related Considerations for Cell Therapies
    • 17.6.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

18. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 18.1. Chapter Overview
  • 18.2. Assumptions and Key Parameters
  • 18.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
    • 18.3.1. Scenario 1
    • 18.3.2. Scenario 2
    • 18.3.3. Scenario 3
    • 18.3.4. Scenario 4
  • 18.4. Concluding Remarks

19. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

  • 19.1. Chapter Overview
  • 19.2. Key Parameters
  • 19.3. Assumptions and Methodology
  • 19.4. Sample Dataset for the Estimation of Total Cost of Ownership
  • 19.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
  • 19.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
    • 19.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
  • 19.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

20. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Scope of the Forecast
  • 20.3. Input Data and Key Assumptions
  • 20.4. Forecast Methodology
  • 20.5. Global Cell Therapy Manufacturing Market, 2022-2035
    • 20.5.1. Cell Therapy Manufacturing Market: Analysis by Type of Cell Therapy, 2022-2035
    • 20.5.2. Cell Therapy Manufacturing Market: Analysis by Source of Cells, 2022-2035
    • 20.5.3. Cell Therapy Manufacturing Market: Analysis by Scale of Operation, 2022-2035
    • 20.5.4. Cell Therapy Manufacturing Market: Analysis by Purpose of Manufacturing, 2022-2035
    • 20.5.5. Cell Therapy Manufacturing Market: Analysis by Region, 2022-2035
  • 20.6. Cell Therapy Manufacturing Market for Commercial Scale Manufacturing
    • 20.6.1. Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035
      • 20.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
      • 20.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region
    • 20.6.2. Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035
      • 20.6.2.1. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.6.2.2. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region
    • 20.6.3. Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
      • 20.6.3.1. Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035: Analysis by Region
    • 20.6.4. Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
      • 20.6.4.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.6.4.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region
  • 20.7. Cell Therapy Manufacturing Market for Clinical Scale Manufacturing
    • 20.7.1. Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035
      • 20.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
      • 20.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region
    • 20.7.2. Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
      • 20.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Region
    • 20.7.3. Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035
      • 20.7.3.1. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.7.3.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region
    • 20.7.4. Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
      • 20.7.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
      • 20.7.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region

21. KEY INSIGHTS

  • 21.1. Chapter Overview
  • 21.2. Cell Therapy Manufacturing: Grid Analysis
  • 21.3. Cell Therapy Manufacturing: Logo Landscape
    • 21.3.1. Immune Cell Therapy Manufacturing: Logo Landscape
    • 21.3.2. Stem Cell Therapy Manufacturing: Logo Landscape
  • 21.4. Cell Therapy Manufacturing: World Map Representation based on Location of Manufacturing Facilities
    • 21.4.1. Industry Players
    • 21.4.2. Non-Industry Players

22. SWOT ANALYSIS

  • 22.1. Chapter Overview
  • 22.2. Strengths
  • 22.3. Weaknesses
  • 22.4. Opportunities
  • 22.5. Threats
  • 22.6. Comparison of SWOT Factors

23. CONCLUDING REMARKS

  • 23.1. Chapter Overview

24. SURVEY ANALYSIS

  • 24.1. Chapter Overview
  • 24.2. Analysis by Designation of Respondents
  • 24.3. Analysis by Type of Cell Therapy
  • 24.4. Analysis by Scale of Operation
  • 24.5. Analysis by Source of Cells
  • 24.6. Analysis by Type of Cell Culture System Used
  • 24.7. Analysis by Availability of Fill / Finish Services

25. INTERVIEW TRANSCRIPTS

  • 25.1. Chapter Overview
  • 25.2. RoslinCT
    • 25.2.1. Company Overview
    • 25.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer
  • 25.3. Discovery Life Sciences
    • 25.3.1. Company Overview
    • 25.3.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell and Gene Therapy
  • 25.4. Glycostem Therapeutics
    • 25.4.1. Company Overview
    • 25.4.2. Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 25.5. Bio Elpida
    • 25.5.1. Company Overview
    • 25.5.2. Interview Transcript: Gilles Devillers, President
  • 25.6. Gracell Biotechnologies
    • 25.6.1. Company Overview
    • 25.6.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 25.7. Kadimastem
    • 25.7.1. Company Overview
    • 25.7.2. Interview Transcript: Arik Hasson, Executive VP Research and Development
  • 25.8. RoslinCT
    • 25.8.1. Company Overview
    • 25.8.2. Interview Transcript: Fiona Bellot, Ex-Business Development Manager
  • 25.9. University of Minnesota
    • 25.9.1. Company Overview
    • 25.9.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine
  • 25.10. Lion TCR
    • 25.10.1. Company Overview
    • 25.10.2. Interview Transcript: Victor Lietao Li, Ex- Co-Founder and Chief Executive Officer
  • 25.11. Center for Commercialization of Cancer Immunotherapy / C3i
    • 25.11.1. Company Overview
    • 25.11.2. Interview Transcript: Arnaud Deladeriere, Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit
  • 25.12. Waisman Biomanufacturing
    • 25.12.1. Company Overview
    • 25.12.2. Interview Transcript: Brian Dattilo, Manager of Business Development
  • 25.13. Yposkesi
    • 25.13.1. Company Overview
    • 25.13.2. Interview Transcript: Mathilde Girard, Ex-Department Leader, Cell Therapy Innovation and Development
  • 25.14. Cell Therapies
    • 25.14.1. Company Overview
    • 25.14.2. Interview Transcript: Tim Oldham, Ex-Chief Executive Officer
  • 25.15. CiMaas
    • 25.15.1. Company Overview
    • 25.15.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제